SBIR Phase II: Electronic Allergy Diagnostics: Photo-Immobilization as a General Strategy for Attaching Structurally and Compositionally Diverse Ligands onto a Single Support

SBIR 第二阶段：电子过敏诊断：光固定化作为将结构和组成多样的配体附着到单一支持物上的一般策略

• 批准号: 1152483
• 负责人: Jeff King
• 金额: $ 48.95万
• 依托单位: Virogenomics, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-01 至 2014-10-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1152483&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Electronic; Allergy

This Small Business Innovation Research (SBIR) Phase II project aims to create better diagnostic testing for drug, food, and environmental allergies. If successful, it would be transformative in the clinical diagnosis of allergy diseases by enabling rapid evaluation at the doctor?s office in a format that is significantly preferable to skin-prick or challenge testing.The broader impacts of this research are the development of next generation diagnostic devices. These devices will enable the diagnosis of many different conditions and diseases with just a small drop of blood, right in a doctor?s office. Disease diagnosis from blood often requires that the blood sample, typically one or more test tubes full of blood, be taken from a vein in a patient?s arm and sent to a clinical laboratory. This is uncomfortable for the patient, requires them to wait days for results, is expensive, and is less safe than the approach being developed by Virogenomics because a large amount of blood that must be transported and handled. The Virogenomics platform will use just a drop of blood and will provide results while the patient is still in the doctor?s office. This diagnostic test works similar to the blood-glucose monitors diabetics use to monitor their blood sugar but is much more flexible in regards to the types of tests that can be done. In addition to allergy diagnosis, the proposed diagnostic platform would have application in many other fields that affect our health, such as diagnostics for autoimmune diseases, infectious disease and cancer.

这个小型企业创新研究(SBIR)第二阶段项目旨在为药物、食品和环境过敏创造更好的诊断测试。如果成功，它将改变过敏疾病的临床诊断，使S医生办公室能够以一种明显优于皮肤针或挑战式测试的形式进行快速评估。这项研究的更广泛影响是下一代诊断设备的开发。S医生的办公室里，这些设备只需一滴血就能诊断出多种不同的疾病和疾病。从血液中诊断疾病通常需要从患者的静脉中提取血液样本，通常是一个或多个装满血液的试管--S手臂，并将其送往临床实验室。这对患者来说是不舒服的，需要他们等待几天才能得到结果，成本很高，而且比病毒基因组学正在开发的方法更不安全，因为必须运输和处理大量的血液。病毒基因组学平台将只使用一滴血，并将在患者仍在医生办公室的情况下提供结果-S。这种诊断测试的工作原理类似于糖尿病患者用来监测血糖的血糖监测仪，但在可以进行的测试类型方面要灵活得多。除了过敏诊断，拟议的诊断平台还将应用于许多其他影响我们健康的领域，如自身免疫性疾病、传染病和癌症的诊断。